GO
Loading...

Enter multiple symbols separated by commas

Stocks Celgene Corp

More

  • Aug 31- Wall Street ended lower on Monday and wrapped up its worst month since 2012 after a senior Federal Reserve official heightened fears among investors of a potential U.S. interest hike in September. Fed Vice Chairman Stanley Fischer on Saturday said U.S. inflation would likely rebound as pressure from the dollar fades, allowing the Fed to raise interest...

  • Celgene Corp has alleged Bass is abusing a process set up to challenge patents by short selling pharmaceutical shares that drop when a patent review is filed. Last month, Celgene, one of the world's largest biotechnology firms, asked the patent office to sanction Bass and others behind the coalition by throwing out its patent challenges. Celgene said Bass' real...

  • UK's AstraZeneca beats profit forecasts Thursday, 30 Jul 2015 | 3:05 AM ET
    Viagra made by Pfizer and Nexium made by AstraZeneca.

    AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter.

  • LONDON, July 30- AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter, as income from spinning off assets offset generic competition to older medicines and a strong dollar. Chief Executive Pascal Soriot, who fended off a $118 billion takeover attempt by Pfizer last year, is banking on a promising pipeline of new drugs-...

  • NEW YORK, July 29- Celgene Corp, one of the world's largest biotechnology companies, has accused U.S. hedge fund manager Kyle Bass of attempting to profit from his attempts to wipe out several major drug patents through his Coalition for Affordable Drugs. Patent and Trademark Office on Tuesday to sanction Bass and others behind the group by throwing out its...

  • *Tecfidera U.S. growth to be flat for rest of 2015. July 24- Biogen Inc more than halved its sales growth forecast for 2015, saying it expects demand for its flagship multiple sclerosis drug, Tecfidera, to continue slowing this year in the United States. Biogen's stock fell as much as 18.8 percent to a seven-month low, wiping out about $17 billion of its value, after the...

  • Brace yourself! Thursday is earnings palooza Thursday, 23 Jul 2015 | 6:13 AM ET
    Trader on the floor of the New York Stock Exchange.

    Amazon.com, Caterpillar, McDonald's and GM are among the 50 odd companies reporting Thursday, making it the busiest day of the earnings season.

  • Brace yourself! Thursday is earnings palooza Wednesday, 22 Jul 2015 | 6:35 PM ET
    Trader on the floor of the New York Stock Exchange.

    Amazon.com, Caterpillar, McDonald's and GM are among the 50 odd companies reporting Thursday, making it the busiest day of the earnings season.

  • New 'trolls' are crushing innovation in biopharma Wednesday, 22 Jul 2015 | 10:16 AM ET
    Biotech pharmaceuticals

    Hedge funds and and a new type of patent troll are using loopholes in patent law for gains, stifling innovation, says author Joseph Gulfo.

  • US STOCKS-Wall Street edges lower as energy weighs Wednesday, 15 Jul 2015 | 4:23 PM ET

    *Bank of America rises after profit more than doubles. "We were positive the whole day and we sort of lost our gains right at the tail end," said Phil Orlando, chief equity market strategist at Federated Investors in New York. "If crude were to be going down, that would mean there is an assumption this deal may get through Congress or the President's veto won't get...

  • *Bank of America rises after profit more than doubles. Brent settled down $1.46 at $57.05 while U.S. crude settled down $1.63 at $51.41 a barrel. The group was buoyed by a 3.4 percent rise in Bank of America to $17.72 and a 3.7 percent gain in U.S. Bancorp to $45.51 after their quarterly results.

  • US STOCKS-Wall St higher; financial stocks lead Wednesday, 15 Jul 2015 | 1:09 PM ET

    *Nasdaq biotech index hits record high on Celgene deal. Celgene jumped as much as 10.7 percent to a record high of $135.98 after the company said it would buy Receptos to get a potential multibillion-dollar drug. Celgene's gains helped push the Nasdaq biotech index to hit a record high for the third time in three weeks.

  • *Nasdaq biotech index hits record high on Celgene deal. *Bank of America rises after profit more than doubles. *Delta Air Lines warning weighs on airline stocks.

  • *Celgene soars on deal to buy Receptos. Celegene's shares jumped as much as 9.4 percent to a record high of $134.34 after the company said it would buy Receptos for $7.2 billion to get a potential multibillion-dollar drug. Receptos jumped 10.4 percent to $228.64, while the Nasdaq biotech index jumped more than 2 percent to hit a record high for the third time in...

  • *Bank of America rises after profit more than doubles. July 15- Wall Street was set to open little changed on Wednesday after Federal Reserve Chair Janet Yellen said the central bank remained on track to raise interest rates this year, with turmoil abroad unlikely to throw the U.S. economy off track. "The fact that the Fed feels comfortable raising rates even with...

  • Celgene to buy Receptos for $7.3B Wednesday, 15 Jul 2015 | 8:00 AM ET
    Celgene to buy Receptos for $7.3B

    Cancer drug company Celgene agrees to pay $7.3 billion for Receptos.

  • Early movers: BLK, BAC, PRNA, DAL, LNKD & more Wednesday, 15 Jul 2015 | 7:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • This drug was key driver of Celegene deal: CEO Wednesday, 15 Jul 2015 | 7:52 AM ET
    This drug was key driver of Celegene deal: CEO

    CNBC's Meg Tirrell and Robert Hugin, Celgene chairman & CEO, discuss the drugmaker's $7.3 billion bid for Receptos in an effort to acquire a third autoimmune drug.

  • July 15- U.S. stock index futures were little changed on Wednesday as investors await Federal Reserve Chair Janet Yellen's comments on raising interest rates and the outcome of a Greek parliament vote on the terms of a third bailout. *Bank of America's quarterly profit more than doubled as legal costs dropped sharply, driving expenses down to their lowest since...

  • July 14- Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis. The Receptos move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics...